Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
78 hedge funds and large institutions have $74M invested in Merrimack Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 17 closing their positions.
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
7% more funds holding
Funds holding: 73 → 78 (+5)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
24% less capital invested
Capital invested by funds: $96.8M → $74M (-$22.8M)
28% less call options, than puts
Call options by funds: $187K | Put options by funds: $260K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.08M |
| 2 |
Millennium Management
New York
|
+$1.67M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.39M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1.1M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$858K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.62M |
| 2 |
Goldman Sachs
New York
|
-$834K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$635K |
| 4 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$623K |
| 5 |
NM
Newtyn Management
New York
|
-$328K |
MACK Hedge Fund Activity: Q4 2017 in Review
78 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2017, worth a combined $74M — down 24% from $96.8M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new MACK positions and 17 closed out — a net gain of 5 holders — while 21 added to existing stakes and 20 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $2.08M. The largest seller was BlackRock, cutting an estimated $2.62M.
- 78 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2017, up from 73 in Q3 2017.
- Funds reported $74M of Merrimack Pharmaceuticals, Inc. stock for Q4 2017, down 24% quarter-over-quarter.
- 22 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2017 and 17 closed out, a net change of +5 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2017 was Dimensional Fund Advisors, an estimated $2.08M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2017 was BlackRock, an estimated $2.62M sold.
Based on aggregated 13F filings for Q4 2017.